Back to Search
Start Over
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
- Source :
-
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2018 May 17; Vol. 66 (11), pp. 1794-1797. - Publication Year :
- 2018
-
Abstract
- Clinical Trials Registration: NCT02263326.
- Subjects :
- Adult
Anti-HIV Agents administration & dosage
Drug Administration Schedule
Drug Resistance, Viral
Heterocyclic Compounds, 3-Ring administration & dosage
Humans
Lamivudine administration & dosage
Oxazines
Pilot Projects
Piperazines
Pyridones
Anti-HIV Agents therapeutic use
HIV Infections drug therapy
HIV-1 drug effects
Heterocyclic Compounds, 3-Ring therapeutic use
Lamivudine therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1537-6591
- Volume :
- 66
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- Publication Type :
- Academic Journal
- Accession number :
- 29293895
- Full Text :
- https://doi.org/10.1093/cid/cix1131